Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasmodium falciparum | 17 | 2013 | 121 | 2.070 |
Why?
|
| Malaria, Falciparum | 6 | 2013 | 81 | 0.920 |
Why?
|
| Merozoite Surface Protein 1 | 7 | 2010 | 34 | 0.910 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2022 | 3 | 0.890 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2022 | 8 | 0.890 |
Why?
|
| Antigens, Protozoan | 11 | 1996 | 71 | 0.770 |
Why?
|
| Antibodies, Protozoan | 12 | 2010 | 77 | 0.720 |
Why?
|
| Health Services, Indigenous | 1 | 2018 | 20 | 0.630 |
Why?
|
| Schools, Medical | 1 | 2018 | 192 | 0.550 |
Why?
|
| Neutrophil Infiltration | 1 | 2015 | 26 | 0.540 |
Why?
|
| Bronchi | 1 | 2015 | 45 | 0.530 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 200 | 0.480 |
Why?
|
| Metabolome | 1 | 2013 | 47 | 0.450 |
Why?
|
| Metabolomics | 1 | 2013 | 76 | 0.440 |
Why?
|
| Protozoan Proteins | 5 | 1994 | 170 | 0.440 |
Why?
|
| Erythrocytes | 1 | 2013 | 107 | 0.430 |
Why?
|
| Epitopes | 4 | 2010 | 145 | 0.420 |
Why?
|
| Drug Prescriptions | 2 | 2021 | 42 | 0.390 |
Why?
|
| Cross Infection | 2 | 2021 | 38 | 0.390 |
Why?
|
| Hospitals | 2 | 2021 | 86 | 0.380 |
Why?
|
| Protein Precursors | 4 | 2002 | 59 | 0.370 |
Why?
|
| Immunoglobulin M | 1 | 2010 | 81 | 0.360 |
Why?
|
| Immunoglobulin G | 1 | 2010 | 232 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 355 | 0.320 |
Why?
|
| Malaria Vaccines | 3 | 2010 | 20 | 0.300 |
Why?
|
| Signal Transduction | 1 | 2015 | 1802 | 0.290 |
Why?
|
| Cytokines | 3 | 2022 | 569 | 0.280 |
Why?
|
| Biomedical Research | 2 | 2021 | 371 | 0.270 |
Why?
|
| Minority Groups | 2 | 2021 | 537 | 0.260 |
Why?
|
| Cell Differentiation | 4 | 2022 | 562 | 0.260 |
Why?
|
| Adjuvants, Immunologic | 3 | 1994 | 106 | 0.240 |
Why?
|
| Antigens, Surface | 5 | 1994 | 39 | 0.240 |
Why?
|
| Genetic Variation | 1 | 2005 | 328 | 0.230 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2022 | 9 | 0.220 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2022 | 9 | 0.220 |
Why?
|
| Interleukin-4 | 1 | 2022 | 69 | 0.220 |
Why?
|
| Humans | 17 | 2022 | 34853 | 0.220 |
Why?
|
| Community-Acquired Infections | 1 | 2021 | 24 | 0.210 |
Why?
|
| Lymphocyte Activation | 1 | 2022 | 222 | 0.210 |
Why?
|
| Ligands | 1 | 2022 | 317 | 0.200 |
Why?
|
| Pneumonia | 1 | 2021 | 50 | 0.200 |
Why?
|
| Peptide Fragments | 2 | 1993 | 298 | 0.190 |
Why?
|
| Drug Utilization | 1 | 2020 | 29 | 0.190 |
Why?
|
| Animals | 19 | 2018 | 14307 | 0.180 |
Why?
|
| Cross Reactions | 4 | 2010 | 83 | 0.180 |
Why?
|
| Leukoencephalopathies | 1 | 2018 | 3 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 63 | 0.170 |
Why?
|
| Behavioral Research | 1 | 2019 | 37 | 0.170 |
Why?
|
| Mice | 11 | 2018 | 5668 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 70 | 0.170 |
Why?
|
| Hospitalization | 1 | 2021 | 370 | 0.170 |
Why?
|
| Minority Health | 1 | 2019 | 81 | 0.170 |
Why?
|
| Seizures | 1 | 2018 | 67 | 0.160 |
Why?
|
| Colombia | 2 | 2010 | 19 | 0.160 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2018 | 58 | 0.160 |
Why?
|
| Axons | 1 | 2018 | 106 | 0.160 |
Why?
|
| Mice, Knockout | 3 | 2018 | 897 | 0.150 |
Why?
|
| Child | 4 | 2021 | 2875 | 0.150 |
Why?
|
| Infant | 3 | 2021 | 1014 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2021 | 1318 | 0.140 |
Why?
|
| Recombinant Proteins | 4 | 2010 | 485 | 0.140 |
Why?
|
| Baculoviridae | 2 | 1993 | 12 | 0.140 |
Why?
|
| Alleles | 3 | 2010 | 284 | 0.140 |
Why?
|
| Genotype | 2 | 2010 | 641 | 0.140 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2015 | 48 | 0.130 |
Why?
|
| Hawaii | 2 | 2020 | 1878 | 0.130 |
Why?
|
| Keratinocytes | 2 | 2006 | 65 | 0.130 |
Why?
|
| Major Histocompatibility Complex | 1 | 1994 | 21 | 0.120 |
Why?
|
| Receptors, Calcitriol | 2 | 2006 | 59 | 0.120 |
Why?
|
| Cyclic ADP-Ribose | 1 | 2013 | 2 | 0.120 |
Why?
|
| Data Mining | 1 | 2013 | 21 | 0.120 |
Why?
|
| Hydrolysis | 1 | 2013 | 86 | 0.110 |
Why?
|
| Glycolysis | 1 | 2013 | 66 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 65 | 0.110 |
Why?
|
| Arginine | 1 | 2013 | 62 | 0.110 |
Why?
|
| Male | 6 | 2021 | 18870 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 984 | 0.110 |
Why?
|
| Rabbits | 5 | 2008 | 278 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2013 | 288 | 0.100 |
Why?
|
| Transcription Factors | 3 | 2006 | 653 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 255 | 0.100 |
Why?
|
| Adolescent | 3 | 2021 | 5035 | 0.100 |
Why?
|
| Canada | 2 | 2021 | 121 | 0.100 |
Why?
|
| Seeds | 1 | 2010 | 34 | 0.100 |
Why?
|
| Papua New Guinea | 1 | 2010 | 20 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 968 | 0.090 |
Why?
|
| Cameroon | 1 | 2010 | 35 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2013 | 878 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 2561 | 0.090 |
Why?
|
| Arabidopsis | 1 | 2010 | 88 | 0.090 |
Why?
|
| Antibody Specificity | 4 | 2008 | 75 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2010 | 155 | 0.090 |
Why?
|
| Protozoan Vaccines | 3 | 1994 | 15 | 0.090 |
Why?
|
| Research Personnel | 2 | 2021 | 133 | 0.080 |
Why?
|
| HIV Infections | 1 | 2022 | 2207 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2022 | 1422 | 0.080 |
Why?
|
| Vaccines, Synthetic | 3 | 2008 | 72 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2021 | 871 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2008 | 445 | 0.080 |
Why?
|
| Middle Aged | 3 | 2020 | 9642 | 0.080 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2006 | 1 | 0.080 |
Why?
|
| Histone Acetyltransferases | 1 | 2006 | 18 | 0.070 |
Why?
|
| Adult | 3 | 2021 | 11034 | 0.070 |
Why?
|
| Phenotype | 3 | 2022 | 650 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 1425 | 0.070 |
Why?
|
| Young Adult | 2 | 2021 | 4012 | 0.070 |
Why?
|
| Amino Acid Sequence | 5 | 2008 | 1124 | 0.070 |
Why?
|
| Trans-Activators | 1 | 2006 | 167 | 0.070 |
Why?
|
| Female | 4 | 2021 | 19873 | 0.070 |
Why?
|
| DNA | 1 | 1988 | 549 | 0.070 |
Why?
|
| Aged | 2 | 2020 | 6448 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 58 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 109 | 0.060 |
Why?
|
| Granulocytes | 1 | 2022 | 28 | 0.060 |
Why?
|
| Immune Sera | 3 | 1992 | 59 | 0.060 |
Why?
|
| Hair Follicle | 1 | 2002 | 6 | 0.050 |
Why?
|
| Actins | 1 | 2022 | 142 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 146 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 1994 | 117 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 1996 | 282 | 0.050 |
Why?
|
| Molecular Sequence Data | 4 | 1996 | 1490 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 53 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 22 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 162 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 78 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2020 | 103 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 1992 | 1530 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Oligodendroglia | 1 | 2018 | 20 | 0.040 |
Why?
|
| Species Specificity | 2 | 1989 | 233 | 0.040 |
Why?
|
| Base Sequence | 2 | 1992 | 932 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2018 | 85 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 577 | 0.040 |
Why?
|
| Neuroglia | 1 | 2018 | 117 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 158 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2021 | 1349 | 0.040 |
Why?
|
| Immunization | 2 | 1992 | 90 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1994 | 41 | 0.030 |
Why?
|
| Immunoblotting | 2 | 1996 | 170 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 2333 | 0.030 |
Why?
|
| Primates | 1 | 1994 | 36 | 0.030 |
Why?
|
| Haplotypes | 1 | 1994 | 152 | 0.030 |
Why?
|
| Epidermis | 2 | 2004 | 26 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 583 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 1993 | 181 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1992 | 23 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1992 | 21 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 84 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1992 | 103 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 1992 | 90 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1992 | 185 | 0.030 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 1991 | 1 | 0.030 |
Why?
|
| Lipid A | 1 | 1991 | 7 | 0.030 |
Why?
|
| Freund's Adjuvant | 1 | 1991 | 14 | 0.030 |
Why?
|
| Neurons | 1 | 2018 | 1130 | 0.020 |
Why?
|
| Vaccination | 1 | 1992 | 259 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1992 | 834 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1989 | 73 | 0.020 |
Why?
|
| United States | 1 | 2019 | 3894 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 195 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1988 | 42 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 30 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1988 | 48 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 93 | 0.020 |
Why?
|
| Malaria | 1 | 1988 | 68 | 0.020 |
Why?
|
| Vaccines | 1 | 1988 | 49 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1988 | 165 | 0.020 |
Why?
|
| Mediator Complex Subunit 1 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2006 | 59 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2006 | 15 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2006 | 154 | 0.020 |
Why?
|
| Water | 1 | 1988 | 283 | 0.020 |
Why?
|
| Mice, Hairless | 1 | 2004 | 8 | 0.020 |
Why?
|
| Dermatitis | 1 | 2004 | 8 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2004 | 39 | 0.020 |
Why?
|
| Permeability | 1 | 2004 | 67 | 0.020 |
Why?
|
| Thiazoles | 1 | 2004 | 71 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 116 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 1442 | 0.010 |
Why?
|
| Intermediate Filament Proteins | 1 | 2002 | 14 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 42 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 1681 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 204 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2002 | 100 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2002 | 323 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 287 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2002 | 486 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 1152 | 0.010 |
Why?
|
| Hybridomas | 1 | 1996 | 28 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 35 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1991 | 25 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1991 | 197 | 0.010 |
Why?
|
| Peptides | 1 | 1991 | 308 | 0.010 |
Why?
|